Filing Flows › Humacyte (HUMA) › Who owns the stock
Who owns Humacyte (HUMA) stock
152 funds reported Humacyte (HUMA) shares in their latest 13F filings, worth $64.4M in all. The largest holder is Vanguard Group ($8.1M). Last quarter 87 funds added to their stakes and 65 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 8,416,971 | $8.1M | increase | 2025-12-31 |
| Antipodes Partners | 10,103,647 | $7.9M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 10,107,679 | $7.9M | increase | 2026-06-30 |
| Alyeska Investment Group, L.P. | 6,022,925 | $4.7M | new | 2026-06-30 |
| Davidson Kempner Capital Management LP | 5,000,000 | $3.9M | new | 2026-06-30 |
| BlackRock | 4,839,929 | $3.8M | decrease | 2026-06-30 |
| Great Point Partners LLC | 3,750,000 | $2.9M | unchanged | 2026-06-30 |
| UBS Group AG | 2,843,493 | $2.2M | increase | 2026-06-30 |
| AQR Capital Management LLC | 2,597,134 | $2.0M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 2,185,225 | $1.7M | decrease | 2026-06-30 |
| Millennium Management LLC | 1,909,049 | $1.5M | increase | 2026-06-30 |
| Susquehanna International Group, LLP | 1,699,243 | $1.3M | increase | 2026-06-30 |
| Citadel Advisors LLC | 1,443,376 | $1.1M | new | 2026-06-30 |
| Charles Schwab Investment Management | 1,353,515 | $1.1M | increase | 2026-06-30 |
| Vanguard Fiduciary Trust | 1,181,276 | $921K | increase | 2026-06-30 |
Humacyte's latest quarter
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most HUMA stock?
By the latest 13F filings: Vanguard Group ($8.1M); Antipodes Partners ($7.9M); Vanguard Capital Management LLC ($7.9M); Alyeska Investment Group, L.P. ($4.7M); Davidson Kempner Capital Management LP ($3.9M).
What is the short interest in HUMA?
30,251,083 shares were sold short at the 2026-10-15 settlement, 2.9% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.